Kymriah involves white blood cells of patients being genetically modified so that they recognise and attack cancer cells
Keystone
Basel-based pharmaceutical company Novartis has received approval for its personalised cell therapy Kymriah in Switzerland. Children and adults who suffer from certain types of blood cancer will be able to undergo the one-time treatment, which is set to cost CHF370,000 ($371,000).
Kymriah is already registered in the US, the EU and other countries. In the US, the treatment costs $475,000; the EU has said it will work with health officials to find fair, value-based pricing.
As in the US, pricing in Switzerland is set to be linked to the success of the therapy, although the details were still being worked out, said Kay Moeller-Heske, head of oncology at Novartis Switzerland, on Monday. The drug is not covered by obligatory health insurance, he added.
Kymriah involves white blood cells of patients being genetically modified so that they recognise and attack cancer cells. Novartis is the first Swiss pharmaceutical company to be approved for such therapy.
The number of possible treatment centres in Switzerland would initially be very limited as the Kymriah cell therapy places high demands on the production facilities and the staff, according to Moeller-Heske.
He pointed out, however, that the number of patients was expected to be very low at first: a “low two-digit number” of patients, with four or five being children.
What is Kymriah and what does it do?
Kymriah, formerly known as CTL019, is a type of immunotherapyExternal link known as a chimeric antigen receptor T cell (CAR-T) therapy, and is first of its kind to receive FDA approval. Kymriah is intended for use in patients with a specific type of childhood leukaemia known as ALLExternal link. It is a one-time treatment that involves modifying a patient’s own T-cells – a type of white blood cell – and then using them to target and destroy cancer cells. Until now, ALL has had a very poor survival rate – fewer than 10% of patients survive five yearsExternal link.
More
More
Will exclusive collaborations yield more drug breakthroughs?
This content was published on
Recently FDA-approved, Novartis’s pioneering immunotherapy was developed through an agreement with University of Pennsylvania researchers.
Swiss price watchdog slams excessive prices for generic medicines
This content was published on
The cheapest generic medicines available in Switzerland are more than twice as expensive as in other countries, according to a study by the Swiss price watchdog.
Nature should not figure in net zero calculations: academic study
This content was published on
The natural removal of CO2 from the atmosphere by forests or oceans should not be included in the net-zero balance of climate protection measures, argue researchers.
This content was published on
None of the 15 major Swiss retail banks is meeting international climate and biodiversity targets, according to a ranking by WWF Switzerland.
This content was published on
Nestlé's new CEO Laurent Freixe, has presented plans for the future of the world's largest food company, after his first few weeks in office.
Swiss foreign minister calls on Moscow to end Ukraine war
This content was published on
It's high time Moscow ended its war against Ukraine, Swiss foreign minister Ignazio Cassis tells the UN Security Council.
This content was published on
The only alternative to the UN Palestinian agency’s work in Gaza is to allow Israel to run services there, Philippe Lazzarini, UNRWA Commissioner-General, told reporters in Geneva on Monday.
Study reveals food culture differences between Switzerland and neighbours
This content was published on
Three-quarters of Swiss people consider eating to be a pleasurable, social activity, a new survey reveals. Healthy eating, however, plays a much less important role, it found.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Novartis’s new $475,000 cancer drug among most expensive ever
This content was published on
Bruno Strigini, chief executive of oncology at Novartis, said: “We carefully considered the appropriate price and looked at many factors, including the medical and clinical value.” He was speaking on Wednesday shortly after the treatment was approved by the US Food and Drug Administration (FDA), which gave Novartis a green light to use the medicine…
This content was published on
The increases are primarily due to demographic changes. There are increasing numbers of old people in the population, and old people tend to have more chronic diseases, said Pascale Strupler, director of the Swiss Federal Office of Public Health, at a press conference on Monday. The good news: the risk of dying from cancer decreased…
Study finds increased paediatric cancer risk near motorways
This content was published on
Researchers from the Institute for Social and Preventive Medicine (ISPM) looked for relationships between proximity to a Swiss motorway and the number of cancer cases registered in children between 1985 and 2008. They found that children growing up within 100 metres of a motorway had a 47% to 57% higher risk of contracting leukaemia. Despite…
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.